Atrial arrhythmias after atrial fibrillation are better managed with dronedarone than sotalol!

(2-butyl-5-nitro-1-benzofuran-3-yl)-[4-[3-(dibutylamino)propoxy]phenyl]methanone is used as the intermediate of Dronedarone .
　　Dronedarone is an antiarrhythmic drug. It is suitable for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), reducing the risk of hospitalization, patients with recent AF / AFL attacks and cardiovascular risk factors, and patients with sinus rhythm or cardioversion. About the pharmacological action, pharmacokinetics, drug interaction, indications and adverse reactions of dronedarone

　　Atrial tachyarrhythmias are common after ablation of atrial fibrillation and are therefore commonly treated with antiarrhythmic drugs, and a recently published study by JAHA suggests that dronedarone is more effective and safer than sotalol after ablation.
　　At 12-month follow-up, the study found that patients treated with dronedarone after AF ablation had a lower risk of cardiovascular hospitalization compared to those treated with sotalol, primarily due to lower rates of hospitalization associated with atrial tachyarrhythmias.
　　Patients treated with sotalol had a significantly lower rate of cardiovascular hospitalization due to atrial tachyarrhythmias compared to patients treated with dronedarone.
　　The rates of cardiovascular hospitalization due to atrial tachyarrhythmias were 27.0% and 38.3% at 3 months, 19.4% and 27.3% at 6 months, and 14.8% and 19.9% at 12 months for dronedarone and sotalol patients, respectively.
　　Dronedarone has a better safety profile compared to sotalol.
　　Dronedarone had fewer arrhythmogenic events, whereas sotalol had a higher risk of arrhythmia and an increased need for pacemaker implantation after AF ablation, mainly caused by the higher risk of significant bradyarrhythmias in sotalol-treated patients.
　　Of the 30,696 patients treated with AF ablation in this retrospective cohort, 2086 were treated with dronedarone after ablation and 3665 were treated with sotalol after ablation. After matching on a 1:1 propensity score, there were 1815 patients treated with dronedarone versus those treated with sotalol, respectively.